Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SPRO Stock Forecast 2026-2027
$2.72
Current Price
$157.46M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SPRO Price Targets
+47.1%
To High Target of $4.00
+47.1%
To Median Target of $4.00
+47.1%
To Low Target of $4.00
SPRO Price Momentum
+11.9%
1 Week Change
+17.2%
1 Month Change
+361.0%
1 Year Change
+16.7%
Year-to-Date Change
-15.5%
From 52W High of $3.22
+438.6%
From 52W Low of $0.51
📊 TOP ANALYST CALLS
Did SPRO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Spero is one of their latest high-conviction picks.
Latest SPRO Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, SPRO has a neutral consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Buy (6.0/10). Currently trading at $2.72, the median forecast implies a 47.1% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SPRO Analyst Ratings
0
Buy
1
Hold
0
Sell
SPRO Price Target Range
Low
$4.00
Average
$4.00
High
$4.00
Current: $2.72
Latest SPRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SPRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 30, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Dec 20, 2024 | Evercore ISI Group | Josh Schimmer | In-Line | Downgrade | $5.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Nov 18, 2024 | TD Cowen | Ritu Baral | Hold | Downgrade | $N/A |
| Nov 15, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
| Oct 3, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Aug 6, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Aug 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Aug 6, 2024 | TD Cowen | Ritu Baral | Buy | Upgrade | $N/A |
| May 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Apr 4, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Mar 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Sep 5, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Aug 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Aug 1, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Jul 20, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Apr 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Sep 26, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
Spero Therapeutics Inc. (SPRO) Competitors
The following stocks are similar to Spero based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SPRO
Spero Therapeutics
mkt cap
140.68M
Spero Therapeutics Inc. (SPRO) Financial Data
Spero Therapeutics Inc. has a market capitalization of $157.46M with a P/E ratio of 17.8x. The company generates $66.80M in trailing twelve-month revenue with a 12.8% profit margin.
Revenue growth is +174.5% quarter-over-quarter, while maintaining an operating margin of +76.0% and return on equity of +16.3%.
Valuation Metrics
Market Cap
$157.46M
Enterprise Value
$117.20M
P/E Ratio
17.8x
PEG Ratio
-0.1x
Price/Sales
2.3x
Growth & Margins
Revenue Growth (YoY)
+174.5%
Gross Margin
N/A
Operating Margin
+76.0%
Net Margin
+12.8%
EPS Growth
+323.9%
Financial Health
Cash/Price Ratio
+25.6%
Current Ratio
7.6x
Debt/Equity
4.9x
ROE
+16.3%
ROA
+5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Spero Therapeutics Inc. (SPRO) Business Model
About Spero Therapeutics Inc.
What They Do
Develops treatments for antibiotic-resistant infections.
Business Model
Spero Therapeutics generates revenue by developing and commercializing novel therapies aimed at treating infections caused by antibiotic-resistant bacteria. Their focus on innovative oral and IV treatment options allows them to address critical healthcare needs, particularly in hospital settings where multi-drug resistant infections are prevalent.
Additional Information
Headquartered in Cambridge, Massachusetts, Spero Therapeutics is at the forefront of combating antibiotic resistance, a pressing issue in global health. By leveraging advanced scientific research and development, the company is positioned to significantly impact public health and safety.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
32
CEO
Ms. Esther P. Rajavelu
Country
United States
IPO Year
2017
Website
sperotherapeutics.comSpero Therapeutics Inc. (SPRO) Latest News & Analysis
Latest News
Quick Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) reported its Q4 and full-year financial results for 2025 and provided a business update, focusing on treatments for rare diseases.
Why It Matters
Spero Therapeutics' financial results and business updates can influence stock performance, signaling growth potential or challenges in their drug development pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) will report Q4 and full year 2025 financial results and provide a business update on March 26, 2026, after market close, without a conference call.
Why It Matters
Spero Therapeutics' upcoming financial report may impact stock performance and investor sentiment, especially regarding its progress in developing treatments for rare diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Spero Therapeutics' tebipenem for cUTI achieved Phase 3 noninferiority and supported GSK's NDA resubmission, with positive interim results from the PIVOT-PO trial.
Why It Matters
Positive Phase 3 results for Spero's tebipenem bolster GSK's NDA resubmission, enhancing investor confidence in potential FDA approval and market success.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Spero Therapeutics announced that GSK has resubmitted a New Drug Application to the FDA for tebipenem HBr, an antibiotic for complicated urinary tract infections.
Why It Matters
The NDA resubmission for tebipenem HBr could lead to FDA approval, potentially boosting Spero Therapeutics' stock value and market position in the antibiotic space.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Spero Therapeutics granted 90,000 restricted stock units to a new employee on November 3, 2025, under its 2019 Inducement Equity Incentive Plan, as approved by its Compensation Committee.
Why It Matters
The grant of RSUs signals Spero's commitment to attracting talent, which can enhance innovation and drive future growth, impacting long-term value for shareholders.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
4 months ago
Quick Summary
Spero Therapeutics announced that GSK will submit data from the PIVOT-PO trial for tebipenem HBr to the FDA in Q4 2025. The company expects cash to fund operations into 2028.
Why It Matters
Spero's positive trial results and upcoming FDA filing could enhance its market position and attract investment, while projected cash flow stability supports operational continuity.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SPRO Stock
What is Spero Therapeutics Inc.'s (SPRO) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Spero Therapeutics Inc. (SPRO) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is SPRO stock a good investment in 2026?
According to current analyst ratings, SPRO has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SPRO stock?
Wall Street analysts predict SPRO stock could reach $4.00 in the next 12 months. This represents a 47.1% increase from the current price of $2.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Spero Therapeutics Inc.'s business model?
Spero Therapeutics generates revenue by developing and commercializing novel therapies aimed at treating infections caused by antibiotic-resistant bacteria. Their focus on innovative oral and IV treatment options allows them to address critical healthcare needs, particularly in hospital settings where multi-drug resistant infections are prevalent.
What is the highest forecasted price for SPRO Spero Therapeutics Inc.?
The highest price target for SPRO is $4.00 from at , which represents a 47.1% increase from the current price of $2.72.
What is the lowest forecasted price for SPRO Spero Therapeutics Inc.?
The lowest price target for SPRO is $4.00 from at , which represents a 47.1% increase from the current price of $2.72.
What is the overall SPRO consensus from analysts for Spero Therapeutics Inc.?
The overall analyst consensus for SPRO is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are SPRO stock price projections?
Stock price projections, including those for Spero Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 9, 2026 10:28 AM UTC